12:10 PM EDT, 09/24/2025 (MT Newswires) -- The European stock markets closed mixed in Wednesday trading as the Stoxx Europe 600 was off 0.14%, Germany's DAX gained 0.30%, the FTSE 100 rose 0.29%, France's CAC declined 0.57%, and the Swiss Market Index fell just over 1%.

In Germany, sentiment among businesses declined in September to 87.7 points from 88.9 points in August, according to the ifo Institute's Business Climate Index. Companies were less satisfied with current business, while expectations dropped sharply, ifo said. The reading was well off the analysts forecast of 89.3, according to Bloomberg.

"Prospects for an economic recovery have suffered a setback," the ifo Institute said. "Any glimmers of hope that had emerged among capital goods manufacturers in the previous month have faded."

And in corporate news, UBS plans to increase payouts for its US wealth advisers starting Jan. 1 as part of the efforts to maintain retention and boost recruitment amid rising competition for talent, Bloomberg reported Tuesday, citing unnamed sources familiar with the matter.

The report said the Swiss bank announced internally earlier this month that advisers generating $1 million to $3 million in revenue will receive higher pay rates, while those generating $3 million to $4 million will receive a higher amount of the payout in cash.

UBS did not immediately respond to requests for comment from MT Newswires.

Shares of the Swiss bank fell 1% in Zurich.

Sanofi and its Winthrop Industrie unit were ordered by a Paris appeals court to pay a fine of 150.7 million euros ($177 million) in damages to France's National Health Insurance Fund for engaging in anti-competitive practices linked to its Plavix anti-clotting medicine, multiple media outlets reported Wednesday.

Sanofi did not immediately respond to a request for comment from MT Newswires.

Shares of the French pharmaceutical company gained 0.30% in Paris.

AstraZeneca said Wednesday the US Food and Drug Administration has granted priority review to its and Daiichi Sankyo's supplemental biologics license application for Enhertu combined with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. The agency's action date for the regulatory decision is expected in Q1 2026, the company said.

Shares of the British pharmaceutical company lost 0.4% on the FTSE 100.

TotalEnergies and Germany's RWE won a French government tender to build the Centre Manche 2 offshore wind farm off the coast of Normandy with a capacity of 1.5 gigawatts, the French government said Wednesday. The project will produce electricity at a guaranteed price of 66 euros ($77.60) per megawatt hour. The consortium also committed to favoring wind turbines and cables manufactured in Europe.

Shares of TotalEnergies rose more than 2% on the CAC.